MerckMRK
MRK
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 1,498 | Existing positions reduced: 1,391
7% more call options, than puts
Call options by funds: $1.98B | Put options by funds: $1.85B
8% less first-time investments, than exits
New positions opened: 146 | Existing positions closed: 159
2% less funds holding
Funds holding: 3,480 [Q2] → 3,420 (-60) [Q3]
3.03% less ownership
Funds ownership: 79.82% [Q2] → 76.78% (-3.03%) [Q3]
12% less capital invested
Capital invested by funds: $251B [Q2] → $221B (-$30B) [Q3]
42% less funds holding in top 10
Funds holding in top 10: 190 [Q2] → 111 (-79) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$105
7%
upside
Avg. target
$119
21%
upside
High target
$130
33%
upside
9 analyst ratings
5 positive
56%
4 neutral
44%
0 negative
0%
Leerink Partners Daina Graybosch 0% 1-year accuracy 0 / 2 met price target | 22%upside $119 | Outperform Maintained | 13 Jan 2025 |
UBS Colin Bristow 12% 1-year accuracy 2 / 17 met price target | 23%upside $120 | Buy Maintained | 8 Jan 2025 |
Truist Securities Robyn Karnauskas 11% 1-year accuracy 3 / 28 met price target | 12%upside $110 | Hold Downgraded | 8 Jan 2025 |
BMO Capital Evan David Seigerman 11% 1-year accuracy 2 / 19 met price target | 7%upside $105 | Market Perform Downgraded | 20 Dec 2024 |
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target | 24%upside $121 | Buy Reinstated | 10 Dec 2024 |
Financial journalist opinion
Based on 42 articles about MRK published over the past 30 days
Positive
Seeking Alpha
20 hours ago
Merck: 3x Pipeline And Undervaluation Make It A Buy
Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance with 7% YoY revenue growth, driven by Keytruda and GARDASIL expansions, supports Merck's solid financial health. Merck's 3.3% dividend yield, low net debt-to-EBITDA ratio, and promising late-stage assets enhance its appeal for value and income-oriented investors.
Positive
Seeking Alpha
23 hours ago
High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Merck's robust Phase 3 pipeline, strong financials, and sustainable dividend make it a compelling investment despite risks like Medicare negotiations and patent expirations. Merck also appears to have good potential for future growth.
Neutral
Reuters
2 days ago
Exclusive: Kennedy played key role in vaccine case against Merck
Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los Angeles court next week, according to two attorneys close to the case and court filings.
Positive
Zacks Investment Research
3 days ago
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Neutral
Forbes
3 days ago
What's In Store For Merck Stock In 2025?
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock(up 15%), Merck's stock performance has been muted.
Positive
Zacks Investment Research
4 days ago
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.
Neutral
Business Wire
4 days ago
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4.
Positive
The Motley Fool
5 days ago
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever
If you're looking at dividend stocks as a source of income, obviously quality matters. But timing can play a role in how much income these investments generate for you, too.
Neutral
CNBC Television
6 days ago
Merck CEO Robert Davis goes one-on-one with Jim Cramer
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.
Positive
CNBC Television
6 days ago
We've seen patients on transplant lists taken off of them after starting Winrevair, says Merck CEO
Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.
Charts implemented using Lightweight Charts™